<DOC>
	<DOCNO>NCT00419770</DOCNO>
	<brief_summary>The purpose study determine addition medication , deferasirox , standard antifungal therapy infection , mucormycosis , safe effective</brief_summary>
	<brief_title>The Deferasirox-AmBisome Therapy Mucormycosis ( DEFEAT Mucor ) Study</brief_title>
	<detailed_description>Because extremely high morbidity mortality , imperative look new antifungal therapy treat mucormycosis . The agent mucormycosis exquisitely sensitive iron availability , others demonstrate iron chelation therapy improve survival rodent mucormycosis . Deferasirox ( Exjade ) first orally bioavailable iron chelator approve use United States ( US ) Food Drug Administration ( FDA ) , indication treatment iron overload chronic transfusion . In clinical study , deferasirox well tolerated effective iron-overloaded patient . Although safety efficacy deferasirox extensively evaluate iron-overloaded patient , minimal data non-iron-overloaded patient infected patient . Therefore , safety efficacy deferasirox patient mucormycosis unclear , confirm safety current study , currently plan dose , require lay groundwork future phase III clinical trial . This prospective , phase II , randomize , double-blinded , placebo-controlled study liposomal amphotericin B ( LAmB ; AmBisome ) plus deferasirox vs. LAmB plus placebo mucormycosis infection . Twenty patient proven probable mucormycosis ( except isolate skin infection ) consensus EORTC/MSG criterion , receive less 14 day antifungal therapy mucormycosis , radiographic image CT MRI within past 72 hour show evidence infection , randomize receive LAmB plus deferasirox placebo ( n = 10 per arm ) , randomization stratify study site . The primary objective determine safety tolerability adjunctive deferasirox therapy patient treat LAmB mucormycosis , obtain exploratory data efficacy iron chelation treatment . The exploratory efficacy endpoint global response rate ( composite clinical radiographic response ) end study drug administration , determine blind adjudication committee .</detailed_description>
	<mesh_term>Mucormycosis</mesh_term>
	<mesh_term>Zygomycosis</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Age great 2 year . Proven probable invasive mucormycosis , define modification consensus European Organization Research Treatment Cancer ( EORTC ) /Mycosis Study Group ( MSG ) criterion . In brief , proven mucormycosis define : 1 ) histopathologic cytopathologic examination show broadbased , aseptate , ribbonlike hypha consistent Mucorales needle aspiration biopsy specimen , evidence associate tissue damage ( either microscopically unequivocally image ) ; OR 2 ) positive culture result sample obtain sterile procedure normally sterile clinically radiologically abnormal site consistent infection , exclude urine mucous membrane . Probable mucormycosis define : 1 ) atrisk host ; AND 2 ) positive culture , cytology , polymerase chain reaction ( PCR ) test ( run CLIAcertified clinical microbiology laboratory ) sputum , bronchoalveolar lavage ( BAL ) , endoscopy/colonoscopy , sinus aspirate/biopsy ; AND 3 ) 1 major 2 minor clinical criterion . Radiographic study Computerized Tomography ( CT ) Magnetic Resonance Imaging ( MRI ) obtain within 4 calendar day prior enrollment show evidence infection ( i.e . focal nodule , mass , abscess , enhancement , evidence tissue edema destruction attribute postsurgical reaction ) . Subject authorized decision maker able provide inform consent . High likelihood death within 48 h enrollment ( investigator 's discretion ) . High likelihood death due factor unrelated mucormycosis ( e.g . due uncontrolled and/or relapse malignancy , severe graft versus host disease , underlie disease , etc . ) within 30 day follow enrollment ( investigator 's discretion ) . Patient unable receive enteral medication ( oral via feed tube ) . Infection limit suprafascial skin ( skin lesion presence disseminate disease , deep invasive tissue infection spread primary skin site , subcutaneous infection extend fascia allow ) . Patient receive &gt; 14 day polyene antifungal therapy ( i.e . amphotericin B deoxycholate , liposomal amphotericin B , amphotericin B lipid complex , amphotericin B colloidal dispersion ) time screen . Patient already take deferasirox therapy reason time screen . Patient allergic intolerant deferasirox LAmB . Patient significant renal dysfunction time screening , define serum creatinine &gt; 3 mg/dL calculate creatinine clearance &lt; 30 ml/min ( CockroftGault formula : ( 140 age ( yr ) * wt ( kg ) ) * 0.85 ( female ) / ( 72 * serum creatinine ( mg/dL ) ) . Patient significant hepatic dysfunction time screening , define BOTH AST ALT &gt; 10 time upper limit normal , AND direct ( total ) bilirubin &gt; 5 time upper limit normal . Women childbearing potential ( menses within last year ) positive serum pregnancy test . Enrollment refuse primary physician .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>zygomycosis</keyword>
	<keyword>Rhizopus</keyword>
	<keyword>iron</keyword>
	<keyword>iron-chelation</keyword>
	<keyword>adjunctive therapy</keyword>
</DOC>